

ONE HUNDRED SIXTEENTH CONGRESS
Congress of the United States
House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-2927
Minority (202) 225-3641

January 2, 2020

Dr. Anthony S. Fauci
Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane
Rockville, MD 20852

Dear Dr. Fauci:

Thank you for appearing before the Subcommittee on Oversight and Investigations on Wednesday, December 4, 2019, at the hearing entitled “Flu Season: U.S. Public Health Preparedness and Response.” We appreciate the time and effort you gave as a witness before the Subcommittee on Oversight and Investigations.

Pursuant to Rule 3 of the Committee on Energy and Commerce, members are permitted to submit additional questions to the witnesses for their responses, which will be included in the hearing record. Attached are questions directed to you from members of the Committee. In preparing your answers to these questions, please address your responses to the member who has submitted the questions using the Word document provided with this letter.

To facilitate the publication of the hearing record, please submit your responses to these questions by no later than the close of business on Thursday, January 16, 2020. As previously noted, this transmittal letter and your responses, as well as the responses from the other witnesses appearing at the hearing, will all be included in the hearing record. Your responses should be transmitted by email in the Word document provided with this letter to Benjamin Tabor with the Committee staff (benjamin.tabor@mail.house.gov). A paper copy of your responses is not required. Using the Word document provided for submitting your responses will also help maintain the proper format for incorporating your answers into the hearing record.

Dr. Anthony S. Fauci
Page 2

Thank you for your prompt attention to this request. If you need additional information or have other questions, please contact Mr. Tabor at (202) 225-2927.

Sincerely,



Frank Pallone, Jr.
Chairman

Attachment

cc: Hon. Greg Walden, Ranking Member, Committee on Energy and Commerce
Hon. Diana DeGette, Chair, Subcommittee on Oversight and Investigations
Hon. Brett Guthrie, Ranking Member, Subcommittee on Oversight and Investigations

**Committee on Energy and Commerce
Subcommittee on Oversight and Investigations**

**Hearing on
“Flu Season: U.S. Public Health Preparedness and Response”**

December 4, 2019

**Anthony S. Fauci, M.D., Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health**

The Honorable Brett Guthrie (R-KY)

1. The National Institutes of Health’s (NIH) written testimony states that the National Institute for Allergy and Infectious Diseases (NIAID) is supporting research to examine how the immune systems of young children respond over time to their initial influenza infection and their first vaccination.
 - a. Is NIAID’s research also examining how the immune systems of adults respond over time to influenza vaccinations?
 - b. Do we have a good understanding on how repeat vaccinations affect the ability of adults to mount an immune response to different influenza subtypes?

The Honorable Jeff Duncan (R-SC)

1. You stated that “historically, the worst bioterrorist has been nature itself” referring to pandemic flu and in your March 14, 2019 testimony to the Senate Appropriations Committee, you testified that stockpiling flu vaccine is not yet possible because it changes from season to season and thus you have supported going “full speed ahead on the platform technologies.” Combined with the government’s stated goal of procuring a vaccine in 12 weeks:
 - a. Do you support pursuing multi-modal platform technologies capable of responding not only to influenza but additional biological threats such as Ebola?
 - b. How important is the speed with which we respond to a pandemic determine our ability to effectively combat it?
 - c. Do you think it’s important to support pursuing multiple, novel technologies to ensure we can produce vaccines rapidly following a pandemic declaration?